| pubmed-article:21486698 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21486698 | lifeskim:mentions | umls-concept:C0003392 | lld:lifeskim |
| pubmed-article:21486698 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21486698 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:21486698 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:21486698 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:21486698 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:21486698 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:21486698 | pubmed:dateCreated | 2011-5-2 | lld:pubmed |
| pubmed-article:21486698 | pubmed:abstractText | A series of novel N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential telomerase inhibitors were synthesized. The bioassay tests show that compound 4a exhibited high activity against human gastric cancer cell SGC-7901, liver cancer Hep-G2 and human prostate PC-3 cell lines with IC(50) values of 21.23±0.99, 29.43±0.32 and 30.89±1.07 ?M, respectively. All title compounds were assayed for telomerase inhibition by a modified TRAP assay, the results show that compound 4a can inhibit telomerase with IC(50) value of 4.0±0.32 ?M. Docking simulation was performed to position compound 4a into the telomerase (3DU6) active site to determine the probable binding model. | lld:pubmed |
| pubmed-article:21486698 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21486698 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21486698 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21486698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21486698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21486698 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21486698 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21486698 | pubmed:month | May | lld:pubmed |
| pubmed-article:21486698 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:MeeSS | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:EstacioR ORO | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:XXX | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:LiuXin-HuaXH | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:ZhuHai-LiangH... | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:SongBao-AnBA | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:RuanBan-FengB... | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:LiuJing-XinJX | lld:pubmed |
| pubmed-article:21486698 | pubmed:author | pubmed-author:QiXing-BaoXB | lld:pubmed |
| pubmed-article:21486698 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21486698 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21486698 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21486698 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:21486698 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21486698 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21486698 | pubmed:pagination | 2916-20 | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:meshHeading | pubmed-meshheading:21486698... | lld:pubmed |
| pubmed-article:21486698 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21486698 | pubmed:articleTitle | Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents. | lld:pubmed |
| pubmed-article:21486698 | pubmed:affiliation | State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China. | lld:pubmed |
| pubmed-article:21486698 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21486698 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:21486698 | lld:chembl |
